Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy
and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at
least one prior therapy.